text
"['\n1. 요약재무정보\n당사는 2018년 9월 19일 발표된 [제약ㆍ바이오 기업의 연구개발비 회계처리 관련 감독지침]을 고려, 개발비 자산화 시점의 회계처리 오류(무형자산 과대계상 및 경상연구개발비 과소계상 등)를 수정하였으며, 이에 따라 제27기(전전기) 재무재표는 소급 재작성되었습니다.\xa0\n가. 요약연결재무정보\xa0\n(단위: 원)\n구 분\n제29기\n제28기\n제27기\n(2019년 12월말)\n(2018년 12월말)\n(2017년 12월말)\n[유동자산]\n1,785,115,919,500\n1,664,281,326,370\n1,614,033,788,024\n\xa0ㆍ현금및현금성자산\n546,137,583,490\n410,547,608,852\n419,205,662,651\n\xa0ㆍ단기금융자산\n81,681,590,783\n121,636,304,845\n138,717,014,000\n\xa0ㆍ매출채권\n814,370,251,982\n807,711,314,915\n828,394,032,126\n\xa0ㆍ기타수취채권\n12,372,205,267\n124,267,624,254\n3,211,880,582\n\xa0ㆍ재고자산\n306,709,922,768\n162,916,820,624\n199,481,840,555\n\xa0ㆍ당기법인세자산\n-\n9,523,563,778\n9,780,837,220\n\xa0ㆍ기타유동자산\n23,844,365,210\n27,678,089,102\n15,242,520,890\n[비유동자산]\n2,074,530,709,558\n1,838,826,878,560\n1,680,062,197,809\n\xa0ㆍ장기금융자산\n17,629,052,511\n18,989,084,041\n15,686,919,883\n\xa0ㆍ장기기타수취채권\n10,733,643,020\n10,287,886,409\n8,562,470,441\n\xa0ㆍ관계기업투자\n47,841,529,392\n28,003,078,925\n17,006,445,302\n\xa0ㆍ유형자산\n923,592,891,742\n881,437,749,875\n844,212,382,151\n\xa0ㆍ무형자산\n1,008,192,903,389\n885,018,659,777\n788,358,689,859\n\xa0ㆍ이연법인세자산\n23,311,280,287\n-\n-\n\xa0ㆍ기타비유동자산\n43,229,409,217\n15,090,419,533\n6,235,290,173\n자산총계\n3,859,646,629,058\n3,503,108,204,930\n3,294,095,985,833\n[유동부채]\n657,225,837,904\n678,087,471,395\n616,781,029,714\n[비유동부채]\n329,507,580,221\n229,761,340,951\n266,817,280,825\n부채총계\n986,733,418,125\n907,848,812,346\n883,598,310,539\n[자본금]\n128,337,853,000\n125,456,133,000\n122,666,424,000\n[주식발행초과금]\n786,358,490,538\n761,047,500,208\n741,748,885,673\n[이익잉여금]\n1,963,727,518,268\n1,665,189,222,641\n1,429,153,613,949\n[기타포괄손익누계액]\n3,000,227,548\n9,970,124,880\n8,720,587,567\n[기타자본항목]\n-121,314,726,197\n-75,159,128,990\n-14,828,853,103\n[비지배지분]\n112,803,847,776\n108,755,540,845\n123,037,017,208\n자본총계\n2,872,913,210,933\n2,595,259,392,584\n2,410,497,675,294\n(2019.01.01~2019.12.31)\n(2018.01.01~2018.12.31)\n(2017.01.01~2017.1.31)\n매출액\n1,128,459,877,886\n982,074,959,799\n949,079,965,214\n영업이익\n381,532,472,575\n323,131,558,365\n499,585,550,587\n법인세비용차감전순이익\n382,031,278,440\n301,639,078,511\n483,071,479,107\n당기순이익\n301,442,694,249\n237,476,360,558\n377,725,080,593\n\xa0ㆍ지배기업소유주지분\n301,030,346,627\n245,755,018,366\n368,221,994,127\n\xa0ㆍ비지배지분\n412,347,622\n-8,278,657,808\n9,503,086,466\n\xa0ㆍ기본주당이익\n2,369\n1,932\n2,898\n연결에 포함된 회사수\n10\xa0\n8\xa0\n6\xa0\n나. 요약재무정보\xa0\n(단위: 원)\n구 분\n제29기\n제28기\n제27기\n(2019년 12월말)\n(2018년 12월말)\n(2017년 12월말)\n[유동자산]\n1,610,730,917,459\n1,482,310,007,849\n1,421,211,524,496\n\xa0ㆍ현금및현금성자산\n526,092,843,365\xa0\n399,558,425,745\n413,501,866,488\n\xa0ㆍ단기금융자산\n79,113,846,512\xa0\n121,636,304,845\n138,402,014,000\n\xa0ㆍ매출채권\n690,252,563,176\xa0\n689,472,264,429\n713,489,012,682\n\xa0ㆍ기타수취채권\n25,476,236,632\xa0\n123,885,214,981\n3,133,116,830\n\xa0ㆍ재고자산\n268,715,675,450\n125,717,441,514\n141,164,307,648\n\xa0ㆍ기타유동자산\n21,079,752,324\xa0\n22,040,356,335\n11,521,206,848\n[비유동자산]\n2,063,791,784,809\n1,888,329,253,915\n1,716,972,980,244\n\xa0ㆍ장기금융자산\n15,406,459,369\xa0\n17,407,490,899\n14,354,326,741\n\xa0ㆍ장기기타수취채권\n9,618,771,557\xa0\n9,141,484,165\n7,169,744,638\n\xa0ㆍ종속기업및관계기업투자\n313,849,033,448\xa0\n286,212,166,532\n273,099,081,283\n\xa0ㆍ유형자산\n701,428,195,334\xa0\n677,870,722,592\n635,989,041,524\n\xa0ㆍ무형자산\n987,732,187,355\n877,141,249,708\n774,478,435,302\n\xa0ㆍ투자부동산\n2,918,466,663\xa0\n5,982,493,446\n6,147,170,166\n\xa0ㆍ기타비유동자산\n32,838,671,083\xa0\n14,573,646,573\n5,735,180,590\n자산총계\n3,674,522,702,268\n3,370,639,261,764\n3,138,184,504,740\n[유동부채]\n517,564,388,814\n548,121,290,075\n491,067,961,229\n[비유동부채]\n286,291,312,657\n218,455,704,094\n242,174,301,750\n부채총계\n803,855,701,471\n766,576,994,169\n733,242,262,979\n[자본금]\n128,337,853,000\xa0\n125,456,133,000\n122,666,424,000\n[주식발행초과금]\n786,358,490,538\xa0\n761,047,500,208\n741,748,885,673\n[이익잉여금]\n2,080,593,620,747\n1,793,330,987,094\n1,556,788,491,161\n[기타포괄손익누계액]\n2,590,862,595\xa0\n5,011,173,208\n4,512,733,369\n[기타자본항목]\n(127,213,826,083)\n(80,783,525,915)\n(20,774,292,442)\n자본총계\n2,870,667,000,797\n2,604,062,267,595\n2,404,942,241,761\n종속ㆍ관계ㆍ공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n(2019.01.01~2019.12.31)\n(2018.01.01~2018.12.31)\n(2017.01.01~2017.1.31)\n매출액\n981,870,268,852\n861,884,226,306\n828,917,201,749\n영업이익\n363,391,097,232\n319,413,201,208\n477,891,619,440\n법인세비용차감전순이익\n369,106,504,865\n296,187,867,991\n468,527,542,691\n당기순이익\n289,754,684,653\n238,274,199,791\n362,083,993,186\n\xa0ㆍ기본주당이익\n2,280\n1,873\n2,850\n']"
